The revenue decline is structural due to the asset-light pivot, but the widening net loss and cash burn are concerning. Watch for further updates on the 1 Pharmacy Technology redemption restructuring — if the remaining ~36% of investors demand repayment, liquidity could be severely strained given only RMB381M in cash and equivalents.
Price Chart
Executive Summary
111, Inc. reported Q2 2026 unaudited results showing a 28.3% YoY revenue decline to RMB2.3 billion ($339M), driven by the strategic shift to an asset-light model and divestiture of underperforming subsidiaries. Net loss widened to RMB31.7 million ($4.7M) from RMB7.3 million a year ago, while the company continues to burn cash and carries a large RMB956.7 million redemption obligation to 1 Pharmacy Technology investors, with 63.8% agreeing to restructured terms.
Key Facts
- Net revenue fell 28.3% YoY to RMB2.3 billion ($339.0 million) from RMB3.2 billion
- Net loss widened to RMB31.7 million ($4.7M) from RMB7.3 million in Q2 2025
- Net loss attributable to ordinary shareholders was RMB39.1 million ($5.8M), up from RMB19.5 million
- Loss from operations of RMB23.2 million vs income from operations of RMB0.1 million a year ago
- Cash and equivalents, restricted cash, and short-term investments fell to RMB381.1 million ($56.2M) from RMB611.3 million at year-end 2025
- Redeemable non-controlling interests of RMB956.7 million ($141.0M) remain outstanding to 1 Pharmacy Technology investors; 63.8% of holders agreed to restructured repayment terms
- Operating cash flow was negative RMB11.4 million in Q2 2026 vs negative RMB61.4 million in Q2 2025
- B2B segment profit fell 29.5% YoY; B2C segment profit fell 17.3% YoY
- Promotional product revenue grew 121% YoY to RMB60.7 million, but remains a small portion of total revenue
Financial Impact
Revenue decline of 28.3% YoY; net loss more than quadrupled to RMB31.7M; cash burn of ~RMB230M in H1 2026; large contingent liability of RMB956.7M
Risk Factors
- Continued revenue contraction as the asset-light transition reduces top-line scale
- Liquidity risk from the RMB956.7 million redemption obligation to 1 Pharmacy Technology investors
- Negative operating cash flow and declining cash reserves may require additional financing
- Widening net losses with no clear path to near-term profitability
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-014069 |
| Document: dp253438_6k.htm | 0000950103-26-014069 |
| Document: 0000950103-26-014069-index-headers.html | 0000950103-26-014069 |
| Document: 0000950103-26-014069-index.html | 0000950103-26-014069 |
| Document: 0000950103-26-014069.txt | 0000950103-26-014069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $2.86 | awaiting T+60 | — | $3.00 (+4.90%) |
Sep 28, 2026 29d ago | 6-K | $3.52 | awaiting T+60 | — | $3.00 (−14.77%) |
Sep 17, 2026 5w ago | SC 13D | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Sep 17, 2026 5w ago | 6-K | $3.54 | awaiting T+60 | — | $3.00 (+15.25%) |
Sep 17, 2026 5w ago | 6-K | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Sep 17, 2026 5w ago | Press Release | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Jun 16, 2026 19w ago | Insider Cluster | $4.45 $3.45 | ▼ −22.47% | ▼ −23.47% | $3.00 (−32.58%) |
Jun 12, 2026 19w ago | Insider Cluster | $4.89 $3.20 | ▲ +34.56% | ▲ +37.82% | $3.00 (+38.65%) |
Jun 4, 2026 20w ago | 6-K | $4.72 $3.46 | ▲ +26.69% | ▲ +28.58% | $3.00 (+36.44%) |
May 29, 2026 21w ago | Insider Cluster | $5.28 $3.53 | ▼ −33.14% | ▼ −34.33% | $3.00 (−43.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers